[go: up one dir, main page]

BRPI0718176B8 - formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida - Google Patents

formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida

Info

Publication number
BRPI0718176B8
BRPI0718176B8 BRPI0718176A BRPI0718176A BRPI0718176B8 BR PI0718176 B8 BRPI0718176 B8 BR PI0718176B8 BR PI0718176 A BRPI0718176 A BR PI0718176A BR PI0718176 A BRPI0718176 A BR PI0718176A BR PI0718176 B8 BRPI0718176 B8 BR PI0718176B8
Authority
BR
Brazil
Prior art keywords
semi
controlled release
solid
extended
preparation
Prior art date
Application number
BRPI0718176A
Other languages
English (en)
Inventor
De Sousa Delgado Anne-Paula
Bourissou Didier
Lacombe Frédéric
Lachamp Laurence
Cherif-Cheikh Roland
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of BRPI0718176A2 publication Critical patent/BRPI0718176A2/pt
Publication of BRPI0718176B1 publication Critical patent/BRPI0718176B1/pt
Publication of BRPI0718176B8 publication Critical patent/BRPI0718176B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida. a invenção atual refere-se a uma formulação semissólida parenteral de liberação prolongada e controlada composta de um oligômero capeado na extremidade e uma substância ativa sem qualquer agente de redução de viscosidade suplementar ou excipiente.
BRPI0718176A 2006-10-27 2007-10-26 formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida BRPI0718176B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291679.6 2006-10-27
EP06291679A EP1917971A1 (en) 2006-10-27 2006-10-27 Substained release formulations comprising very low molecular weight polymers
PCT/EP2007/009318 WO2008049631A1 (en) 2006-10-27 2007-10-26 Sustained release formulations comprising very low molecular weight polymers

Publications (3)

Publication Number Publication Date
BRPI0718176A2 BRPI0718176A2 (pt) 2013-12-17
BRPI0718176B1 BRPI0718176B1 (pt) 2018-06-05
BRPI0718176B8 true BRPI0718176B8 (pt) 2021-05-25

Family

ID=37907031

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718176A BRPI0718176B8 (pt) 2006-10-27 2007-10-26 formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida

Country Status (14)

Country Link
US (1) US9724397B2 (pt)
EP (3) EP1917971A1 (pt)
JP (2) JP5410980B2 (pt)
CN (1) CN101528249B (pt)
BR (1) BRPI0718176B8 (pt)
CA (1) CA2667424C (pt)
DK (1) DK2086567T3 (pt)
ES (1) ES2610400T3 (pt)
HU (1) HUE032387T2 (pt)
MX (1) MX2009004332A (pt)
PL (1) PL2086567T3 (pt)
PT (1) PT2086567T (pt)
RU (1) RU2453329C2 (pt)
WO (1) WO2008049631A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705520C (en) 2007-11-13 2016-06-28 Surmodics Pharmaceuticals, Inc. Viscous terpolymers as drug delivery platform
US8822546B2 (en) 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US9480643B2 (en) 2008-12-23 2016-11-01 Surmodics Pharmaceuticals, Inc. Implantable composites and implants comprising same
US8974808B2 (en) 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
DE102009018013A1 (de) † 2009-04-18 2010-10-21 Qualimed Innovative Medizin-Produkte Gmbh Beschichteter Stent
US9993441B2 (en) 2009-12-30 2018-06-12 Surmodics, Inc. Controlled release matrix barrier structure for subcutaneous medical devices
WO2012030819A1 (en) 2010-08-30 2012-03-08 Surmodics Pharmaceuticals, Inc. Terpolymers as pressure-sensitive adhesives
US20140107025A1 (en) * 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
US10224258B2 (en) * 2013-03-22 2019-03-05 Applied Materials, Inc. Method of curing thermoplastics with microwave energy
CN104117056B (zh) * 2013-04-28 2016-08-10 上海现代药物制剂工程研究中心有限公司 载胎盘生长因子纳米粒及其制备方法和应用
DK3137532T3 (da) 2014-05-01 2021-08-02 Ingell Tech Holding B V Flydende triblok-copolymer
TW202247855A (zh) 2016-09-13 2022-12-16 美商愛力根公司 非蛋白梭菌毒素組成物
US20220354783A1 (en) 2018-08-01 2022-11-10 Edix-O Sarl Injectable prolonged-action compositions for use in the treatment of nail disease and/or for promoting nail growth
EP3603650A1 (fr) 2018-08-01 2020-02-05 Edix O Sarl Compositions injectables et a duree d'action prolongee pour leur utilisation dans le traitement de maladies de l'ongle et/ou pour accelerer la croissance de l'ongle

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE353658B (pt) * 1967-06-13 1973-02-12 Dow Corning
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
JP3524195B2 (ja) * 1994-02-21 2004-05-10 武田薬品工業株式会社 徐放性製剤用基剤
CA2143044C (en) * 1994-02-21 2005-04-12 Yasutaka Igari Matrix for sustained-release preparation
WO1995033490A1 (en) * 1994-06-02 1995-12-14 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
CA2228118A1 (en) * 1995-07-28 1997-02-13 Focal, Inc. Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatments agents
US6211249B1 (en) * 1997-07-11 2001-04-03 Life Medical Sciences, Inc. Polyester polyether block copolymers
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
GB2354438A (en) * 1999-09-23 2001-03-28 Procter & Gamble Polymer based compositions with anti-hydrolytic enzyme activity for use in pharmaceutical and cosmetic preparations
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
CA2440394C (en) * 2001-05-07 2011-10-04 Cornell Research Foundation, Inc. Biodegradable copolymers linked to segment with a plurality of functional groups
JP4615862B2 (ja) * 2001-12-18 2011-01-19 ノボ・ノルデイスク・エー／エス 固形投与マイクロインプラント
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
WO2004012703A1 (en) 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US7309757B2 (en) * 2003-06-20 2007-12-18 Agency For Science, Technology And Research Polymers for the delivery of bioactive agents and methods of their preparation
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
WO2006078320A2 (en) * 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
PT1786400E (pt) * 2004-08-12 2009-06-19 Quest Pharmaceutical Services Composições farmacêuticas para a libertação controlada de compostos biologicamente activos
US8007775B2 (en) * 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
ES2397712T3 (es) * 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
PL2010184T3 (pl) * 2006-04-06 2013-07-31 Nupathe Inc Implanty do leczenia stawów związanych z dopaminą

Also Published As

Publication number Publication date
JP2010507612A (ja) 2010-03-11
RU2009120005A (ru) 2010-12-10
DK2086567T3 (en) 2017-01-23
RU2453329C2 (ru) 2012-06-20
JP5410980B2 (ja) 2014-02-05
JP5778741B2 (ja) 2015-09-16
EP1917971A1 (en) 2008-05-07
EP2086567A1 (en) 2009-08-12
US9724397B2 (en) 2017-08-08
CA2667424A1 (en) 2008-05-02
BRPI0718176A2 (pt) 2013-12-17
CN101528249B (zh) 2013-04-17
EP3141257A1 (en) 2017-03-15
BRPI0718176B1 (pt) 2018-06-05
PL2086567T3 (pl) 2017-05-31
EP2086567B1 (en) 2016-10-19
HUE032387T2 (en) 2017-09-28
ES2610400T3 (es) 2017-04-27
MX2009004332A (es) 2009-06-16
CN101528249A (zh) 2009-09-09
CA2667424C (en) 2018-05-22
US20100209384A1 (en) 2010-08-19
JP2014015488A (ja) 2014-01-30
PT2086567T (pt) 2017-01-17
WO2008049631A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
BRPI0718176B8 (pt) formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
AR054581A1 (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
BRPI0811317A2 (pt) Combinação, embalagem farmcêutica, kit ou mbalagem par apaciente, agente auxiliar, compsoto, usos de um agente auxiliar e de um composto, e, processo para a produção de uma combinação
BR112014005134A2 (pt) composição farmacêutica de dissolução rápida
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112013025519A2 (pt) composição farmacêutica
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
BR112014018378A8 (pt) Processo contínuo para a preparação de um comprimido compreendendo ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
BRPI0821616B8 (pt) composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma
BR112014029762A2 (pt) composição contendo n-metil-n-acilglucamina
BR112014026117A2 (pt) composições para higiene pessoal
BR112012006642A2 (pt) composição oftálmica aquosa injetável e método para uso da mesma
BR112014004460A2 (pt) material polimérico para um recipiente isolado
BRPI0905369B8 (pt) composição farmacêutica, uso da composição farmacêutica e kit compartimentado
BRPI0909630B8 (pt) composição em suspensão aquosa particularmente adequada para injeção dentro do olho
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
BRPI0821555A2 (pt) Componente para uma vaciana de hiv ou massa, componente ou massa líquida liofilizados, composição farmacêutica ou vacina, usos do componente ou massa final ou da composição farmacêutica e de um antioxidante com pelo menos um grupo funcional tiol e métodos de tratamento e de reconstituição de um componente liofilizado, e kit
BR112014028069A2 (pt) composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica
CL2007003587A1 (es) Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
AR059927A1 (es) Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2693 DE 16-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.